Business Context and Reporting Period
This Form 8-K Current Report was filed by Enochian Biosciences, Inc. (trading symbol: ENOB) on March 24, 2021, covering events that occurred on March 18, 2021. The registrant is a Delaware corporation headquartered in Los Angeles, California. Note: The request metadata references "Lunai Bioworks Inc.," but the filing text explicitly identifies the registrant as "Enochian Biosciences, Inc."
Key Financial Metrics
The filing details a specific capital raise event rather than periodic financial performance metrics (e.g., revenue, net income, or operating cash flow).
- Capital Raised: $3,400,800 in aggregate proceeds.
- Shares Issued: 867,555 shares of common stock.
- Price Per Share: $3.92.
- Transaction Type: Private placement under Regulation S.
- Underwriting: None; the company did not engage an underwriter or placement agent.
The filing text does not provide clear values for revenue, profit, margins, total debt, or liquidity positions outside of the proceeds from this specific transaction.
Material Changes
The primary material change reported is the increase in equity capital and outstanding share count resulting from the private placement. Additionally, the company reported a material scientific development regarding findings published in the peer-reviewed American Journal of Case Reports.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (Exhibit 99.1) regarding the aforementioned scientific findings. The filing explicitly states that the company undertakes no duty or obligation to update or revise the information included in the report or the exhibit.
Risks and Contingencies: The private placement was conducted pursuant to Regulation S, requiring that all investors are not "U.S. persons" as defined by Rule 902. The company did not engage in general solicitation or advertising.
Investor Verification Checklist
- Verify the exact number of shares issued (867,555) and the total proceeds ($3,400,800) to confirm dilution impact.
- Review Exhibit 99.1 (Press Release) to understand the specific scientific findings in the American Journal of Case Reports and their potential commercial implications.
- Confirm the terms of the Subscription Agreement (Exhibit 10.1) for any specific covenants or restrictions on the new shares.
- Check subsequent filings for updated financial statements to assess how the $3.4 million proceeds affect the company's overall liquidity and cash runway.